PDCD1 and familial pancreatic carcinoma: In terms of clinical treatment, the combination of existing immune checkpoint inhibitors (such as PD-1/PD-L1 antibody) and gemcitabine chemotherapy scheme has not shown a stable and significant therapeutic advantage in unselected patients with pancreatic cancer.